STOCK TITAN

BETTERLIFE PHARMA INC - BETRF STOCK NEWS

Welcome to our dedicated page for BETTERLIFE PHARMA news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on BETTERLIFE PHARMA stock.

BETTERLIFE PHARMA INC (BETRF) is a pharmaceutical company dedicated to developing innovative therapies for mental health disorders and neurological conditions. With a focus on research and development, the company is at the forefront of advancements in treatment options. BETRF's strong financial position and strategic partnerships enhance its ability to bring novel products to market.

Rhea-AI Summary
BetterLife Pharma Inc. completes 4-week toxicology study for BETR-001, showing well-tolerated repeat dosing and broad therapeutic window in humans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
Rhea-AI Summary
BetterLife Pharma announces potential for treating mood disorders with BETR-001, closes private placement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced that its collaborators from Carleton University will present findings on BETR-001, a non-hallucinogenic LSD derivative, at the SOBP Conference, April 27-29, 2023, in San Diego. Preclinical data indicate that BETR-001 enhances stress-coping behaviors and reverses anxiety and depression in mouse models, correlating with increased neuroplasticity in the prefrontal cortex. Driven by the serotonin 5-HT2A receptor, these effects position BETR-001 as a promising candidate for treating mood disorders without the regulatory challenges of traditional psychedelics. CEO Ahmad Doroudian noted that ongoing IND-enabling studies will pave the way for human trials. BetterLife's proprietary patents protect BETR-001, facilitating potential self-administration and broader patient access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.9%
Tags
conferences clinical trial
-
Rhea-AI Summary

BetterLife Pharma Inc., a biotechnology company focused on mental disorder treatments, announced that its CEO Dr. Ahmad Doroudian and COO Dr. Hooshmand Sheshbaradaran will present at the Bloom Burton Healthcare Investor Conference on April 26, 2023, in Toronto.

This prominent event invites leading public and promising private companies in the healthcare sector to connect with global investors. Attendees can expect presentations and one-on-one meetings.

BetterLife is advancing two compounds, BETR-001 and BETR-002, targeting neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic LSD derivative, while BETR-002 is based on honokiol from magnolia bark.

For registration details, visit the Bloom Burton website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

BetterLife Pharma Inc. has announced the publication of an article on its lead candidate BETR-001 (2-bromo-LSD), highlighting its potential for treating depression without hallucinations. The article, featured in Drug Discovery & Development, elaborates on BETR-001's positive preclinical data and safety profile compared to LSD, developed in partnership with notable scientists. The company is advancing BETR-001 towards human clinical trials post-IND-enabling studies. BetterLife also develops other compounds for neuro-psychiatric and neurological disorders, including BETR-002. The management emphasizes the significant therapeutic potential of BETR-001 in neuro-psychiatric conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
Rhea-AI Summary

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced on March 22, 2023, that Medical Xpress published an article discussing its lead candidate, BETR-001 (2-bromo-LSD), aimed at treating mood disorders. The article describes the positive data from the pharmacological characterization of BETR-001, conducted with renowned scientists. CEO Ahmad Doroudian highlighted BETR-001's therapeutic potential and improved safety profile compared to LSD, with human clinical trials projected to commence after IND-enabling studies. BetterLife is focused on developing innovative treatments for neuro-psychiatric disorders, including BETR-002, based on honokiol.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.94%
Tags
none

FAQ

What is the current stock price of BETTERLIFE PHARMA (BETRF)?

The current stock price of BETTERLIFE PHARMA (BETRF) is $0.07527 as of December 20, 2024.

What is the market cap of BETTERLIFE PHARMA (BETRF)?

The market cap of BETTERLIFE PHARMA (BETRF) is approximately 10.1M.

What is the core focus of BETTERLIFE PHARMA INC?

BETRF focuses on developing innovative therapies for mental health disorders and neurological conditions.

What sets BETRF apart from other pharmaceutical companies?

BETRF's strong emphasis on research and development, as well as strategic partnerships, distinguishes it in the industry.

How can I contact Investor Relations at BETRF?

You can reach out to David Melles, Investor Relations Manager, at David.Melles@blifepharma.com or call 1-778-887-1928.

Does BETRF have any recent achievements?

BETRF is known for its advancements in treatment options for mental health disorders and neurological conditions, reflecting its commitment to innovation.

What is the goal of BETTERLIFE PHARMA INC?

BETRF aims to improve the quality of life for individuals affected by mental health disorders through the development of cutting-edge therapies.

How can I stay informed about BETRF's latest developments?

Keep up to date with the latest news and updates from BETRF to stay informed about their progress in the pharmaceutical industry.

Is BETRF actively involved in research and development?

Yes, BETRF places a strong emphasis on R&D to drive innovation and bring novel products to the market.

What are some of BETRF's strategic partnerships?

BETRF collaborates with key partners to enhance its capabilities in developing and commercializing new therapies for mental health disorders.

Where is BETTERLIFE PHARMA INC headquartered?

BETRF is headquartered in a key location, allowing it to access top talent and resources in the pharmaceutical industry.

What is the vision of BETTERLIFE PHARMA INC?

BETRF envisions a future where individuals have access to advanced treatments that significantly improve their mental health and well-being.

BETTERLIFE PHARMA INC

OTC:BETRF

BETRF Rankings

BETRF Stock Data

10.12M
92.71M
27.53%
Biotechnology
Healthcare
Link
United States of America
Vancouver